HIV Reservoirs and Treatment Strategies toward Curing HIV Infection

被引:6
作者
Matsuda, Kouki [1 ,2 ]
Maeda, Kenji [1 ]
机构
[1] Kagoshima Univ, Joint Res Ctr Human Retrovirus Infect, Kagoshima 8908544, Japan
[2] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo 1628655, Japan
关键词
HIV; HIV reservoir; Shock and Kill; Block and Lock; HIV cure; latency-reversing agents; CD4(+) T-CELLS; HISTONE DEACETYLASE INHIBITOR; LATENT-VIRUS REACTIVATION; ANTIRETROVIRAL THERAPY; IN-VIVO; DIDEHYDRO-CORTISTATIN; PERSISTENCE; REPLICATION; ANTIBODIES; AIDS;
D O I
10.3390/ijms25052621
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Combination antiretroviral therapy (cART) has significantly improved the prognosis of individuals living with human immunodeficiency virus (HIV). Acquired immunodeficiency syndrome has transformed from a fatal disease to a treatable chronic infection. Currently, effective and safe anti-HIV drugs are available. Although cART can reduce viral production in the body of the patient to below the detection limit, it cannot eliminate the HIV provirus integrated into the host cell genome; hence, the virus will be produced again after cART discontinuation. Therefore, research into a cure (or remission) for HIV has been widely conducted. In this review, we focus on drug development targeting cells latently infected with HIV and assess the progress including our current studies, particularly in terms of the "Shock and Kill", and "Block and Lock" strategies.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Understanding HIV Compartments and Reservoirs
    Svicher, Valentina
    Ceccherini-Silberstein, Francesca
    Antinori, Andrea
    Aquaro, Stefano
    Perno, Carlo Federico
    CURRENT HIV/AIDS REPORTS, 2014, 11 (02) : 186 - 194
  • [32] Potential Strategies for an HIV Infection Cure
    Lafeuillade, Alain
    HIV CLINICAL TRIALS, 2011, 12 (03): : 121 - 130
  • [33] The Proviral Reservoirs of Human Immunodeficiency Virus (HIV) Infection
    Murzin, Andrey I.
    Elfimov, Kirill A.
    Gashnikova, Natalia M.
    PATHOGENS, 2025, 14 (01):
  • [34] The challenge of viral reservoirs in HIV-1 infection
    Blankson, JN
    Persaud, D
    Siliciano, RF
    ANNUAL REVIEW OF MEDICINE, 2002, 53 : 557 - 593
  • [35] DOLUTEGRAVIR HIV Integrase Inhibitor Treatment of HIV Infection
    Wainberg, Mark A.
    Quashie, Peter K.
    Mesplede, Thibault
    DRUGS OF THE FUTURE, 2012, 37 (10) : 697 - 707
  • [36] Current Treatment of HIV Infection
    Kurtaran, Behice
    MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2015, 4
  • [37] Treatment of HIV infection with raltegravir
    Chirch, Lisa M.
    Morrison, Sidonie A.
    Steigbigel, Roy T.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (07) : 1203 - 1211
  • [38] Targeting the Brain Reservoirs: Toward an HIV Cure
    Marban, Celine
    Forouzanfar, Faezeh
    Ait-Ammar, Amina
    Fahmi, Faiza
    El Mekdad, Hala
    Daouad, Fadoua
    Rohr, Olivier
    Schwartz, Christian
    FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [39] TENOFOVIR ALAFENAMIDE FUMARATE FOR THE TREATMENT OF HIV INFECTION
    Sampath, R.
    Zeuli, J.
    Rizza, S.
    Temesgen, Z.
    DRUGS OF TODAY, 2016, 52 (11) : 617 - 625
  • [40] Current treatment of HIV infection
    Portsmouth, S
    Stebbing, J
    Gazzard, B
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (13) : 1458 - 1466